Calidi Biotherapeutics

We want to welcome @CalidiBio (NYSE: CLDI) to the @benchmark 12th Annual Discovery One-On-One Investor Conference. Learn more on @b2idigital at b2idigital.com/12th-annual-b… Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit calidibio.com. We look forward to seeing the continued results from Allan Camaisa, Boris Minev, MD, Steve Thesing, Andrew Jackson, Wendy Pizarro, Esq., Antonio F. Santidrian, Amish Patel, Ph.D., David Sans, FAARM, PhD, MBA, Barbara H., Thomas Herrmann and the rest of the Calidi Biotherapeutics team! Thank you to our friends at Benchmark for orchestrating this influential conferences year after year. We're honored to work with Richard Messina, Michael Fiorini, Jacqueline Messina, Michael Jacobs, Evangeline Tiara Wilson, John Borer, Pat Alianiello, Edward Rubin, William Sutherland, Robert Bell and the rest of their team. Qualified Investors, please visit benchmarkconferences.com/12t… requests will be reviewed by a representative of Benchmark. Upon approval, you will be contacted and provided additional information.